Abdulrhman H.M. Muhaisen

Dr. Abdulrhman H.M. Muhaisen

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2026 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
AMAbdulrhman H.M. Muhaisen
Abdulrhman H.M. Muhaisen
AAAyham Assaf
Ayham Assaf
MAMohammad Aleidi
Mohammad Aleidi
FAFaris Al-Rabba
Faris Al-Rabba
MAMohammad Al-Nayef
Mohammad Al-Nayef
MQMahdi Qasaymeh
Mahdi Qasaymeh

19 August 2026 in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Verified
Journal Article
Open access
PDF file
AMAbdulrhman H.M. Muhaisen
Abdulrhman H.M. Muhaisen
BRBalqees Mohammed M. Rawashdeh
Balqees Mohammed M. Rawashdeh
Background: Ischemic stroke is a major cause of mortality and long-term neurological disability worldwide. Although conventional vascular risk factors explain a substantial proportion of ischemic stroke burden, genetic susceptibility may contribute to inter-individual and population-level differences in risk. The angiotensin-converting enzyme insertion/deletion (ACE I/D) polymorphism is a biologically plausible vascular candidate variant because of its relationship with ACE activity, renin-angiotensin system regulation, endothelial function, vascular remodeling, and blood-pressure control. However, findings from Middle Eastern populations remain inconsistent. Objective: To systematically evaluate and quantitatively synthesize the association between ACE I/D polymorphism and ischemic stroke susceptibility in populations from the Middle East, with inferences restricted to the countries represented in the eligible evidence—Turkey, Egypt, Iran, and Iraq. Methods: This PRISMA 2020–based systematic review and meta-analysis was prospectively registered in PROSPERO (CRD420261406483). PubMed/MEDLINE, Scopus, and Web of Science were searched from inception to May 23, 2026 for observational genetic association studies reporting ACE I/D genotype or allele data in ischemic stroke cases and stroke-free Middle Eastern controls. Two reviewers independently conducted study selection, data extraction, and Newcastle-Ottawa Scale quality assessment. Random-effects ORs with 95% CIs were pooled under allele, dominant, recessive, homozygous, and heterozygous models, with sensitivity analyses excluding studies with HWE deviation, reconstructed counts, historical controls, and other strict-quality concerns. Results: Ten studies including 1,317 ischemic stroke cases and 979 controls were included, representing Turkey, Egypt, Iran, and Iraq. Across all primary random-effects models, ACE I/D polymorphism was not significantly associated with ischemic stroke susceptibility. The pooled estimates were: allele contrast D vs. I, OR = 1.16 (95% CI: 0.97–1.38); dominant model DD + ID vs. II, OR = 1.20 (95% CI: 0.91–1.57); recessive model DD vs. ID + II, OR = 1.20 (95% CI: 0.89–1.61); homozygous model DD vs. II, OR = 1.26 (95% CI: 0.94–1.70); and heterozygous model ID vs. II, OR = 1.14 (95% CI: 0.84–1.55). Heterogeneity ranged from low to moderate across most models, with the highest heterogeneity observed in the recessive model. Sensitivity analyses, particularly the exclusion of two studies with control-group Hardy–Weinberg equilibrium deviation, consistently attenuated the pooled estimates toward the null and did not support a robust association. Conclusion: Available evidence does not demonstrate a statistically robust association between ACE I/D polymorphism and ischemic stroke susceptibility in the populations studied in Turkey, Egypt, Iran, and Iraq. Although D-allele and DD-genotype carriers showed a weak non-significant trend toward increased risk, this pattern was not stable under sensitivity analyses. Given the null pooled findings, modest evidence base, predominance of unadjusted genotype-derived estimates, and absence of reliable stroke subtype-specific data, the current evidence does not support ACE I/D genotyping for clinical ischemic stroke risk prediction. These findings should not be generalized to Middle Eastern countries for which eligible evidence was unavailable.

24 February 2026 in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Verified
Journal Article
Open access
PDF file
AMAbdulrhman H.M. Muhaisen
Abdulrhman H.M. Muhaisen
OAOssama M. AbuSuailik
Ossama M. AbuSuailik
BRBalqees Mohammed M. Rawashdeh
Balqees Mohammed M. Rawashdeh
RARawan Tayseer Aljohar
Rawan Tayseer Aljohar
BKBielasan Mohammad Khlefat
Bielasan Mohammad Khlefat
SDSara Dhaher
Sara Dhaher
Background: Migraine is a common multifactorial neurovascular disorder with a substantial genetic component. The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism has been implicated in migraine susceptibility, particularly migraine with aura, through its effects on folate metabolism and homocysteine regulation. However, findings remain inconsistent across populations, and evidence from the Middle East is limited. Objective: To systematically evaluate the association between the MTHFR C677T polymorphism and migraine susceptibility among populations from countries represented in the eligible evidence (Turkey, Iran, Egypt). Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines and prospectively registered in PROSPERO (CRD420251164175). Electronic databases (PubMed, PMC, and DOAJ) were searched up to October 9, 2025. Eligible studies included case–control investigations assessing MTHFR C677T polymorphism in migraine patients and controls from countries represented in the eligible evidence (Turkey, Iran, Egypt). Findings were synthesized narratively due to heterogeneity in study design, populations, and outcome reporting. Study quality was assessed using the Newcastle–Ottawa Scale. Results: Six case–control studies comprising 793 migraine patients and 848 controls met the inclusion criteria. Most included studies reported a significant association between the MTHFR C677T polymorphism and increased migraine susceptibility, particularly among individuals carrying the TT genotype. The association was more consistently observed in migraine with aura compared to migraine without aura, although several studies also reported a relationship with migraine without aura. One study did not find a significant overall association. Evidence regarding other MTHFR variants, including A1298C and rs4846049, was limited and inconsistent across studies. Conclusion: This systematic review suggests a consistent association between the MTHFR C677T polymorphism, particularly the TT genotype, and migraine susceptibility in populations from countries represented in the eligible evidence (Turkey, Iran, Egypt). Several included studies indicate a stronger relationship with migraine with aura, supporting the potential involvement of MTHFR-related metabolic pathways in migraine pathophysiology. The observed patterns highlight the possible influence of regional genetic and environmental factors; however, the absence of quantitative synthesis limits the ability to estimate pooled effect sizes.
1

3 August 2026 in Current Problems in Surgery
Verified
Journal Article
Open access
MAMohammad Al-Magableh
Mohammad Al-Magableh
AMAbdulrhman H.M. Muhaisen
Abdulrhman H.M. Muhaisen
BRBalqees Mohammed M. Rawashdeh
Balqees Mohammed M. Rawashdeh

14 October 2026 in JACC
Verified
Journal Article
Closed access
AMAbdulrhman H.M. Muhaisen
Abdulrhman H.M. Muhaisen

29 July 2026 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
BRBalqees Mohammed M. Rawashdeh
Balqees Mohammed M. Rawashdeh
AMAbdulrhman H.M. Muhaisen
Abdulrhman H.M. Muhaisen